Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations for the Treatment of Patients With HER2-Positive Early Breast Cancer (EBC)

Trial Profile

Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations for the Treatment of Patients With HER2-Positive Early Breast Cancer (EBC)

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2016

At a glance

  • Drugs Trastuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary)
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 09 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top